infographic
HIV Prevention Product Overview
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
Improving how prevention is delivered
Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.
AVAC’s work supports:
infographic
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
report
Getting PrEP Rollout Right This Time: Lessons from the Field examines key insights from the rollout of oral PrEP and early introduction of injectable CAB and the dapivirine vaginal ring to inform a faster, smarter and more equitable introduction of future HIV prevention tools, including long-acting injectable PrEP, such as lenacapavir.
presentation
AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
Integrating PrEP and contraception in a single pill to expand choices.
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Overcoming access challenges to new PrEP options.
Hard-won gains in access to essential medicines, vaccines, and diagnostics are under siege from political retreat, corporate profiteering, and deadly funding cuts. Yet governments building local production and increasing domestic health investment, multilateral initiatives expanding pooled procurement and financing, and civil society breaking drug monopolies prove that progress is possible when lives are valued over profits. This event will chart how the world can keep advancing access to medicines—because retreat is not an option.
AVAC welcomes parallel announcements from the Gates Foundation and Unitaid on strategic investments to accelerate the development of, access to and price reduction for generic versions of injectable lenacapavir (LEN), the highly effective six-monthly injection for HIV PrEP.
The 12th SAAIDS Conference 2025, under the theme: Unite for Change – Empower Communities and Redefine Priorities for HIV/AIDS will be held in Johannesburg 8-11 September.